Screener
Gilead Sciences GILD Genvoya — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| HIV | ||||||||
| Biktarvy | $2,981 | $468 | $323 | $3,772 | $2,799 | $429 | $302 | $3,530 |
| Descovy | 921 | 23 | 23 | 967 | 601 | 24 | 28 | 653 |
| Genvoya | 236 | 37 | 16 | 289 | 322 | 40 | 16 | 377 |
| Odefsey | 171 | 58 | 10 | 239 | 221 | 66 | 11 | 298 |
| Symtuza - Revenue share(1) | 105 | 30 | 3 | 138 | 88 | 33 | 3 | 124 |
| Yeztugo | 223 | — | 9 | 232 | 15 | — | — | 15 |
| Other HIV(2) | 23 | 24 | 10 | 56 | 50 | 33 | 9 | 92 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's genvoya — total revenues?
- Gilead Sciences (GILD) reported genvoya — total revenues of $289M in Q2 2026.
- How has Gilead Sciences's genvoya — total revenues changed year-over-year?
- Gilead Sciences's genvoya — total revenues decreased by 23.3% year-over-year, from $377M to $289M.
- What is the long-term trend for Gilead Sciences's genvoya — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's genvoya — total revenues has grown at a -15.1% compound annual growth rate (CAGR), from $2.88B to $1.5B.
- What does genvoya — total revenues mean?
- This metric represents the total gross sales generated by a specific pharmaceutical product line within the company's HIV treatment portfolio. It reflects the market demand, pricing power, and competitive positioning of this specific therapeutic agent over a given fiscal period. Tracking this revenue stream is essential for assessing the lifecycle stage and commercial contribution of key assets within the broader infectious disease segment.
Ask your AI about Gilead Sciences's genvoya — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude